


Claims

1. A compound of formula I



wherein

- 5 R¹ represents a C₁₋₄ alkoxy group optionally substituted by one or more fluoro, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, halo, cyano, a group OSO₂C₁₋₄alkyl wherein the alkyl group is optionally substituted with one or more fluorine atoms, a group NR^aR^b in which R^a and R^b independently represent H or a C₁₋₄alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7
- 10 membered heterocyclic ring optionally including an O, a group CONR^cR^d in which R^c and R^d independently represent H or a C₁₋₄alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring,

n represents 0, 1, 2 or 3 ;

R² represents a C₁₋₄alkyl group optionally substituted by one or more fluoro or a C₁₋₄alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C₁₋₄alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group CONR^cR^d in which R^c and R^d independently represent H or a C₁₋₄alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

m represents 0 or 1;

R³ represents H or a C₁₋₄ alkyl group;

L¹ represents a (CH₂)_pC₃₋₁₀ cycloalkyl(CH₂)_q group in which p and q are independently selected from 0 and 1 and in which the cycloalkyl group may be monocyclic or bicyclic and

25 optionally may be bridged provided that the two nitrogens bearing R³ and R⁴, respectively, are not linked to the same carbon atom, and wherein one of the carbons may be replaced by O or, alternatively, the group -N(R³)-L¹- or the group L¹-N(R⁴) together represent a saturated

bicyclic heterocyclic ring containing from 2 to 9 carbon atoms and the nitrogen bearing R³ or R⁴ respectively;

R⁴ represents H or a C₁₋₄ alkyl group optionally substituted by one or more of the following:

fluoro or C₁₋₄ alkoxy optionally substituted by one or more fluoro;

5 L² represents an alkylene chain (CH₂)_s in which s represents 1, 2 or 3 wherein the alkylene chain is optionally substituted by one or more of the following: fluoro or C₁₋₄ alkyl;

or L² may also represent a 5-6 membered carbocyclic ring fused to R⁵,

R⁵ represents phenyl or naphthyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl, quinolinyl, indolyl, benzofuranyl, benzo[b]thienyl, imidazolyl, benzimidazolyl,

10 thiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, imidazo[1,2-*a*]pyridinyl, 5H-pyrrolo[2,3-*b*]pyrazinyl, 1*H*-pyrrolo[3,2-*c*]pyridinyl, 1*H*-pyrrolo[2,3-*c*]pyridinyl, 1*H*-

pyrrolo[2,3-*b*]pyridinyl, 1*H*-indazolyl, 1*H*-pyrrolo[3,2-*h*]quinolinyl, 1*H*-pyrrolo[3,2-*b*]pyridinyl, 2,1,3-benzothiadiazolyl, 2,1,3-benzoxadiazolyl, quinazolinyl or triazolyl wherein

each R⁵ is optionally substituted by one or more of the following: cyano, halo, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, a C₁₋₄ alkoxy group optionally substituted by one or more fluoro, or by a group S(O)_aR^y in which a is 0, 1 or 2 and R^y is phenyl

15 optionally substituted by cyano, halo, a C₁₋₄ alkyl group optionally substituted by one or more fluoro or a C₁₋₄ alkoxy group optionally substituted by one or more fluoro, or by a group O_z(CH₂)_wR^z in which z and w independently are 0 or 1 and R^z represents phenyl or a

20 heterocyclic group selected from thienyl, pyridyl, thiazolyl, pyrazolyl, wherein each R^z is optionally substituted by one or more of the following: cyano, halo, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, or a C₁₋₄ alkoxy group optionally substituted by one or more fluoro;

as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts,

25 thereof;

with the proviso that when

R¹ represents a C₁₋₄ alkoxy group optionally substituted by one or more fluoro or a C₁₋₄ alkyl group optionally substituted by one or more fluoro; and

n represents 0 or 1; and

R² represents a C₁₋₄alkyl group optionally substituted by one or more fluoro or a C₁₋₄alkoxy group optionally substituted by one or more fluoro ; and

m represents 0 or 1; and

R³ represents H or a C₁₋₄alkyl group; and

5 L¹ represents a cyclohexyl group wherein the two nitrogens bearing R³ and R⁴, respectively, are linked to the cyclohexyl group either via the 1,3 or the 1,4 positions of the cyclohexyl group or L¹ represents a cyclopentyl group wherein the two nitrogens bearing R³ and R⁴, respectively, are linked to the cyclopentyl group via the 1,3 position of the cyclopentyl group; and

10 L² represents an alkylene chain (CH₂)_s in which s represents 1, 2 or 3 wherein the alkylene chain is optionally substituted by one or more of the following: a C₁₋₄alkyl group; and

R⁵ represents aryl wherein aryl means phenyl or naphthyl each of which is optionally substituted by one or more of the following: halo, a C₁₋₄alkyl group or phenyl, or

R⁵ represents a heterocyclic group wherein the term heterocyclic group means thienyl, furyl,

15 pyridyl, pyrrolyl, quinolinyl, indolyl, benzofuranyl or benzo[b]thienyl each of which is optionally substituted by one or more of the following: halo or a C₁₋₄alkyl group ;


or L² represents a C₅₋₆cycloalkyl group which is fused to an R⁵ which is phenyl or a heteroaryl group selected from thienyl, furyl or pyrrolyl;

then R⁴ does not represent H or a C₁₋₄alkyl group; and excluding 1,4-anhydro-2,3,5-trideoxy-

20 3-[(3,4-dichlorophenyl)methyl]amino]-5-[(4-ethoxy-2-quinolinyl)amino]- D-erythro-pentitol

2. A compound as claimed in claim1 in which L¹ represents a monocyclic -(CH₂)_pC₅-6(CH₂)_q- cycloalkyl group in which p and q are independently 0 or 1 wherein there are 3 carbon atoms between the two nitrogens bearing R³ and R⁴, respectively, wherein one of the 25 carbons of the cycloalkyl group may be replaced by O or the group -N(R³)-L¹-, or the group L¹-N(R⁴), together represent a saturated heterocyclic ring containing from 4 to 6 carbon atoms and the nitrogen bearing R³ or R⁴ respectively.

3. A compound according to claim 1 or claim 2 of formula



in which

R^1 represents chloro, fluoro, methoxy or a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4} alkyl group.

5 n represents 0,1 or 2 and when $n=1$ the substituent is attached to either position 6 or 7;

R^2 represents a C_{1-4} alkyl group or a C_{1-4} alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4} alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4} alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

10 m represents 0 or 1;

R^3 represents H;

A represents CH_2 and t is 0 or 1;

15 R^4 represents H;


L^2 represents CH_2 , $C(CH_3)_2$ or CF_2 ; and

R^5 represents aryl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl, quinolinyl, indolyl, benzofuranyl, benzo[*b*]thienyl, imidazolyl, benzimidazolyl, thiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, imidazo[1,2-*a*]pyridine, 5*H*-pyrrolo[2,3-

20 *b*]pyrazine, 1*H*-pyrrolo[3,2-*c*]pyridine, 1*H*-pyrrolo[2,3-*c*]pyridine, 1*H*-pyrrolo[2,3-*b*]pyridine, 1*H*-indazole each of which is optionally substituted by one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4} alkoxy group optionally substituted by one or more fluoro, or by a group $S(O)_aR^y$ in which a is 0, 1 or 2 and R^y is phenyl optionally substituted by cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro or a C_{1-4} alkoxy group optionally substituted by one or more fluoro, or by a

group $O_z(CH_2)_wR^z$ in which z and w independently are 0 or 1 and R^z represents phenyl or a heterocyclic group selected from thienyl, pyridyl, thiazolyl, pyrazolyl, wherein each R^z is optionally substituted by one or more cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4} alkoxy group optionally substituted by one or more fluoro as well as 5 optical isomers and racemates thereof as well as pharmaceutically acceptable salts thereof.

4. A compound according to any previous claim of formula IB



10 in which

R^1 represents H, methoxy, dimethylamino, chloro or fluoro;

R^2 represents H, a C_{1-4} alkyl group or a C_{1-4} alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4} alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a 15 saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4} alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

R^3 represents H;

20 A represents CH_2 and t is 0 or 1;


R^4 represents H;

L^2 represents CH_2 , $C(CH_3)_2$ or CF_2 ; and

R^5 represents 2-thienyl, 3-thienyl, indol-3-yl, 2-pyrrolyl, 5-pyrimidinyl, 4-thiadiazolyl, pyrazolyl, or quinolin-2-yl each of which is optionally substituted by one or more of the 25 following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4}

alkoxy group optionally substituted by one or more fluoro and in addition when R^5 is 2-thienyl it is optionally additionally substituted by pyridyl, 2-thienyl or 3-pyrazolyl each of which is optionally substituted by halo or a C_{1-4} alkyl group optionally substituted by one or more fluoro and when R^5 is indol-3-yl it is optionally additionally substituted by 1- (thiazol-5-yl) methyl which is optionally substituted by halo.

5. A compound according to any previous claim of formula IC



10 in which

R^1 represents H, methoxy, dimethylamino, chloro or fluoro;

R^2 represents H, a C_{1-4} alkyl group or a C_{1-4} alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4} alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4} alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

R^3 represents H;

20 A represents CH_2 and t is 0 or 1;

R^4 represents H;

L^2 represents CH_2 , $C(CH_3)_2$ or CF_2 ; and

R^5 represents 2-thienyl, 3-thienyl, indol-3-yl, 2-pyrrolyl, 5-pyrimidinyl, 4-thiadiazolyl, pyrazolyl, 1*H*-pyrrolo[3,2-b]pyridinyl or quinolin-2-yl each of which is optionally substituted by one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one

or more fluoro, a C₁₋₄ alkoxy group optionally substituted by one or more fluoro and in addition when R⁵ is 2-thienyl it is optionally additionally substituted by pyridyl, 2-thienyl or 3-pyrazolyl each of which is optionally substituted by halo or a C₁₋₄ alkyl group optionally substituted by one or more fluoro and when R⁵ is indol-3-yl it is optionally additionally substituted by 1-(thiazol-5-yl) methyl which is optionally substituted by halo.

6. A compound as claimed in any one of claims 1 to 5 in which p is 0, q is 0 and L¹ is 1,3-cyclohexyl.

7. A compound as claimed in any previous claim in which the two nitrogen atoms are in a trans orientation on the cycloalkyl ring.

8. A compound as claimed in claim 7 wherein the absolute configuration of the cycloalkyl carbon atoms to which the nitrogen atoms are attached is S, S.

9. A compound according to any previous claim in which R⁵ represents one of the following :

1*H*-pyrrolo[3,2-*c*]pyridinyl;

15 1*H*-pyrrolo[2,3-*b*]pyridinyl;

1*H*-indazolyl ;

1-imidazo[1,2-*a*]pyridinyl;

5*H*-pyrrolo[2,3-*b*]pyrazinyl;

1*H*-pyrrolo[3,2-*b*]pyridinyl;

20 1*H*-pyrrolo[3,2-*h*]quinolinyl;

2,1,3-benzothiadiazolyl ; and

2,1,3-benzoxadiazolyl;

wherein each of these heterocycles is optionally substituted by one or more of the following:

cyano, halo, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, a C₁₋₄ alkoxy

25 group optionally substituted by one or more fluoro, or by a group S(O)_aR^y in which a is 0, 1 or 2 and R^y is phenyl optionally substituted by cyano, halo, a C₁₋₄ alkyl group optionally substituted by one or more fluoro or a C₁₋₄ alkoxy group optionally substituted by one or more fluoro, or by a group O_z(CH₂)_wR^z in which z and w independently are 0 or 1 and R^z represents phenyl or a heterocyclic group selected from thienyl, pyridyl, thiazolyl, pyrazolyl, wherein 30 each R^z is optionally substituted by one or more of the following: cyano, halo, a C₁₋₄ alkyl

group optionally substituted by one or more fluoro, or a C₁₋₄alkoxy group optionally substituted by one or more fluoro.

10. A compound as claimed in any previous claim in which L¹ represents a (CH₂)_pC₃₋₁₀ cycloalkyl(CH₂)_q group in which p and q are independently selected from 0 and 1 and in
5 which the cycloalkyl group may be monocyclic or bicyclic and optionally may be bridged provided that the two nitrogens bearing R³ and R⁴, respectively, are not linked to the same carbon atom, and wherein one of the carbons may be replaced by O or, alternatively, the group -N(R³)-L¹- or the group L¹-N(R⁴) together represent a saturated bicyclic heterocyclic ring containing from 2 to 9 carbon atoms and the nitrogen bearing R³ or R⁴ respectively; with
10 the proviso that L¹ is not 1,4-cyclohexyl or 1,3-cyclopentyl.

11. One or more of the following compounds:

N,N-dimethyl-2-[(3-{{(5-pyridin-2-yl-2-thienyl)methyl}amino}cyclohexyl)amino]-quinoline-4-carboxamide;

(1*S,3S*)-*N*-(6-chloro-4-methylquinolin-2-yl)-*N'*-(1-methyl-1*H*-indol-3-yl)methyl]cyclohexane-1,3-diamine;

(1*S,3S*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-(3-thienylmethyl)cyclohexane-1,3-diamine;

(1*R,3R*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-(3-thienylmethyl)cyclohexane-1,3-diamine;

(1*S,3S*)-*N*-(6-fluoro-4-methoxyquinolin-2-yl)-*N'*-(3-thienylmethyl)cyclohexane-1,3-diamine;

(1*S,3S*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-(1-methyl-1*H*-indol-3-yl)methyl]cyclopentane-1,3-diamine;

N-(6-chloroquinolin-2-yl)-*N'*-(3-thienylmethyl)cyclohexane-1,3-diamine;

N-(6-chloroquinolin-2-yl)-*N'*-(1-methyl-1*H*-pyrrol-2-yl)methyl]cyclohexane-1,3-diamine;

N-(6-chloroquinolin-2-yl)-*N'*-(quinolin-3-ylmethyl)cyclohexane-1,3-diamine;

*N*⁶,*N*⁶-dimethyl-*N*²-{3-[(3-thienylmethyl)amino]cyclohexyl}quinoline-2,6-diamine;

25 (1*S,3S*)-*N*-[(4-chloro-1-methyl-1*H*-pyrazol-3-yl)methyl]-*N'*-(6-methoxy-4-methylquinolin-2-yl)cyclopentane-1,3-diamine;

(1*S,3S*)-*N*-(6-methoxy-4-methylquinolin-2-yl)-*N'*-(1,2,3-thiadiazol-4-ylmethyl)cyclopentane-1,3-diamine;

(1*S,3S*)-*N*-(6-methoxy-4-methylquinolin-2-yl)-*N'*-(5-pyridin-2-yl-2-thienyl)methyl]cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(*{*1-[*(*2-chloro-1,3-thiazol-5-yl*)*methyl*)*-1*H*-indol-3-yl*}* methyl*)*-*N*¹-(6-methoxy-4-methylquinolin-2-yl)cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-methoxy-4-methylquinolin-2-yl)-*N*¹-(*{*5-[1-methyl-5-(trifluoromethyl)-1*H*-pyrazol-3-yl*)*-2-thienyl*}* methyl*)*cyclopentane-1,3-diamine;

5 (1*S*,3*S*)-*N*-(2,2'-bithien-5-ylmethyl)-*N*¹-(6-methoxy-4-methylquinolin-2-yl)cyclopentane-1,3-diamine;

*N*⁴,*N*⁴-dimethyl-*N*²-*{*3-[*(*3-thienylmethyl*)*amino*)*cyclohexyl*}* quinoline-2,4-diamine;

*N*⁴,*N*⁴-dimethyl-*N*²-*[*3-*{*[*(*2-(phenylsulfonyl)-1,3-thiazol-5-yl*)*methyl*)*amino*-*

cyclohexyl*]*quinoline-2,4-diamine;

10 *N*²-*(*3-*{*[*(*2,4-dimethoxypyrimidin-5-yl*)*methyl*)*amino*}*cyclohexyl*-**N*⁴,*N*⁴-dimethylquinoline-2,4-diamine;

3-(6-methoxy-4-methylquinolin-2-yl)-*N*-methyl-*N*-(3-thienylmethyl)-3-azabicyclo[3.2.1]octan-8-amine;

15 6-methoxy-4-methyl-*N*-[*((*1*R*,2*S*)-2-*{*[*(*1-methyl-1*H*-indol-3-yl*)*methyl*)*amino*}*cyclopentyl*)*methyl*]*quinolin-2-amine;

(1*S*,3*S*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N*¹-[(1-methyl-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)methyl]cyclopentane-1,3-diamine;

(1*S*,3*S*)-3-*[**{*3-[*(*7-methoxy-4-methylquinolin-2-yl*)*amino*)*cyclopentyl*}* amino*)*methyl*]-*1-methyl-1*H*-indole-6-carbonitrile;

20 (1*S*,3*S*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N*¹-[(1-methyl-1*H*-indol-2-yl)methyl]cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N*¹-*{*1-[3-(trifluoromethyl)pyridin-2-yl]-1*H*-indol-3-yl*}* methyl]cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N*¹-[(1-methyl-1*H*-indazol-3-yl)methyl]cyclopentane-1,3-diamine;

25 (1*S*,3*S*)-*N*-(7-methoxy-4-methylquinolin-2-yl)-*N*¹-*{*1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl*}* methyl]cyclopentane-1,3-diamine;

3-*[**((*1*S*,3*S*)-3-*[*(7-methoxy-4-methylquinolin-2-yl*)*amino*)*cyclopentyl*}* amino*)*methyl*]-*1-methyl-1*H*-indole-5-carbonitrile;

(1*S,3S*)-*N*-{[5-difluormethoxy-1*H*-indol-3-yl]methyl}-*N'*-(7-methoxy-4-methylquinolin-2-yl)cyclopentane-1,3-diamine;

(1*S,2S,4R,6S*)-*N*-(6-methoxy-4-methylquinolin-2-yl)-*N'*-(3-thienylmethyl)bicyclo[2.2.1]heptane-2,6-diamine;

5 (1*R,2S,4S,6S*)-*N*-(6-methoxy-4-methylquinolin-2-yl)-*N'*-(3-thienylmethyl)bicyclo[2.2.1]heptane-2,6-diamine;

(1*S,2S,4R,6S*)-*N*-(7-methoxy-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-indol-3-yl)methyl]bicyclo[2.2.1]heptane-2,6-diamine;

10 (1*S,3S*)-*N*-(7-methoxy-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-pyrrolo[3,2-*b*]quinolin-3-yl)methyl]cyclopentane-1,3-diamine;

(1*S,3S*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl)methyl]cyclopentane-1,3-diamine;

15 (1*S,3S*)-*N*-(7-methoxy-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-pyrrolo[3,2-*b*]pyridin-3-yl)methyl]cyclopentane-1,3-diamine;

(1*S,3S*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-(imidazo[1,2-*a*]pyridin-3-ylmethyl)cyclopentane-1,3-diamine;

(1*S,3S*)-*N*-{[5-(Benzylxy)-1-methyl-1*H*-indol-3-yl]methyl}-*N'*-(7-methoxy-4-20 methylquinolin-2-yl)cyclopentane-1,3-diamine;

(1*S,3S*)-*N*-(7-Methoxy-4-methylquinolin-2-yl)-*N'*-[3-(trifluoromethoxy)benzyl]cyclohexane-1,3-diamine;

(1*S,3S*)-*N*-(2,1,3-Benzothiadiazol-4-ylmethyl)-*N'*-(7-methoxy-4-methylquinolin-2-yl)cyclohexane-1,3-diamine;

25 (1*S,3S*)-*N*-[(1,3-Dimethyl-1*H*-pyrazol-4-yl)methyl]-*N'*-(7-methoxy-4-methylquinolin-2-yl)cyclohexane-1,3-diamine; and

(1*S,3S*)-*N*-(2-Bromo-4-methoxybenzyl)-*N'*-(7-methoxy-4-methylquinolin-2-yl)cyclohexane-1,3-diamine;

and pharmaceutically acceptable salts thereof.

30 12. A compound of formula I as claimed in any previous claim for use as a medicament.


13. A pharmaceutical formulation comprising a compound of formula I, as defined in any one of claims 1 to 11 and a pharmaceutically acceptable adjuvant, diluent or carrier.

14. Use of a compound of formula I, as defined in any one of claims 1 to 11 in the preparation of a medicament for the treatment or prophylaxis of conditions associated with
5 obesity.

15. A method of treating obesity, psychiatric disorders, anxiety, anxi-depressive disorders, depression, bipolar disorder, ADHD, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders and pain related disorders, comprising administering a pharmacologically effective amount of a compound
10 as claimed in any one of claims 1 to 11 to a patient in need thereof.

16. A compound as defined in any one of claims 1 to 11 for use in the treatment of obesity.

17. A process for the preparation of compounds of formula I comprising reacting a compound of formula II



II

15

in which R¹, R², R³, R⁴, L¹, n and m are as previously defined with a compound of formula III




III

20

in which R⁵ is as previously defined and L^{2'} represents a group which after reaction of compounds II and III gives L² on reduction, under reductive alkylation conditions.

18. Intermediates of formula II



in which R^1 , R^2 , R^3 , R^4 , L^1 , n and m are as defined in claim 1.

19. A compound of formula V selected from one or more of:

- 5 (1*S*, 3*S*)-Dibenzyl-cyclohexane-1,3-diylbiscarbamate; and
- (1*S*, 3*S*)-Cyclohexane-1,3-diamine dihydrochloride.

20. A method of treating obesity, type II diabetes, Metabolic syndrome and prevention of type II diabetes comprising administering a pharmacologically effective amount
10 of a compound as claimed in any one of claims 1 to 11 to a patient in need thereof.